Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
about
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesDevelopment of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancerMinireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancersProgesterone receptor modulates ERα action in breast cancer.Trop-2 is a determinant of breast cancer survivalEpigenetic regulation in estrogen receptor positive breast cancer--role in treatment responseEstrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?Deciphering the divergent roles of progestogens in breast cancer.Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.Pathways to tamoxifen resistance.Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.MicroRNA regulation of progesterone receptor in breast cancerEpidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomesThe role of the pathologist in the decision-making process.Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling indexImaging progesterone receptor in breast tumors: synthesis and receptor binding affinity of fluoroalkyl-substituted analogues of tanaproget.Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epitheliumProteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study.The role of Ki-67 in the proliferation and prognosis of breast cancer molecular classification subtypesThe relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancerMethylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome.Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapyTracking progesterone receptor-mediated actions in breast cancerManipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?Molecular portrait-based correlation between primary canine mammary tumor and its lymph node metastasis: possible prognostic-predictive models and/or stronghold for specific treatments?Selected antioxidants and risk of hormone receptor-defined invasive breast cancers among postmenopausal women in the Women's Health Initiative Observational Study.Stratified pathway analysis to identify gene sets associated with oral contraceptive use and breast cancer.Lobular carcinoma of the breast with gastrointestinal metastasis.Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis"Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer.Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patientsBreast cancer - one term, many entities?Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.Hormone-receptor expression and survival patterns in operated cases of female invasive ductal breast carcinoma in Kerala: a retrospective cohort study.
P2860
Q26743510-8D39FA18-85C5-43DB-A773-E5CCCCDD82C1Q26825584-8972832B-2704-49E3-8AE0-6435B4546ECBQ27016106-E262409A-99C0-4F13-A2E5-E071C03A8F4FQ27316268-B90431B3-0E25-4A98-9D43-7C4F09CAD3E2Q27333611-9D60FAE0-2593-45AE-AB11-51AFFD36E32AQ27694612-AE3181E1-6F55-4B30-A783-BA7C4D9E3075Q27851630-9EF952CE-E66C-47C4-8D59-AE204F37D91DQ28084982-F59839A4-ADAA-486F-A9FD-2D6164058EEAQ30240711-C26CBD0A-DDF9-45D7-8AF6-70B2EC418F3FQ30378787-63E66E98-B4D5-495F-96C3-D3AE41B0F8D6Q30441001-2C2650B9-1BBC-49B3-90DC-4ADAB71A9E22Q31031200-29007FD9-42AF-43CB-9844-B048B8B2AF09Q33468636-91642A6F-E6DC-46B5-9AA4-86D34A8EE029Q33688484-E664A97C-FD99-4EE4-BF77-DB280FD1BEC3Q33691211-B81A832F-DC6F-4D7C-8A8D-EB0A9AC424D5Q33697907-F4BFE4A9-3445-4011-A71C-C7202F922A7BQ33717341-719DDDE9-1D7A-4B0C-99E8-14169B876D17Q33909035-F09FD757-8E03-45B7-B54D-8959EEC4F0CCQ33939890-D23DFC74-3E5A-4D7F-A9DD-647B087022C7Q33951695-6224D262-1A51-42E5-875F-0543CAC38C23Q34048140-FA8284F8-BCB7-4C0E-9D4D-ED23D76FCF93Q34109691-2CF8994F-8912-4AE1-9AA0-98D965380BBCQ34171441-EAC8AF9C-429D-46CA-AB71-D4C830F93D29Q34245787-6DCE5DC8-9261-4732-B90E-993FFF39CC7AQ34303319-EA49CE14-AD11-43CF-BBE6-72931992C42CQ34371359-1D5BC758-92F0-4F34-A1D4-1C43C14ABA55Q34388848-29FC9BF2-564E-482D-83D1-0A289AD766A0Q34417159-49A8CAF0-C608-4765-B817-E724E97D8D66Q34475233-9A29A4E3-2D39-4881-B5D2-6C4D7EFFDA0BQ34590323-5A059B4B-C628-4D3C-A46B-7013CEEAB0F7Q34680457-D10C59FA-A561-4F2A-8219-23D8E38F6B2AQ34689083-A6490F25-6DDD-4C5D-AD7C-5EA033222CD5Q34793924-70D7671C-E4B9-4B6B-8A05-13148E0A99EDQ34973200-0A0D20F4-9283-4569-8B85-709462DF2644Q35051765-5F6166B7-6DED-427A-9EF1-BA6BC3EB209DQ35100037-CEF42210-98C0-4B69-BDD3-951C03B66133Q35167133-6EF2AF2D-DCCC-479A-8F6F-2064529E2AFDQ35370118-4AD84D3B-B2FD-4BE3-BEDF-0BA1828B5827Q35412323-20B12419-2332-43A6-8751-BB9A6C28801DQ35537892-162D523E-0C94-42A4-AFE4-D921D2411688
P2860
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Progesterone receptor status s ...... large breast cancer databases.
@en
Progesterone receptor status s ...... large breast cancer databases.
@nl
type
label
Progesterone receptor status s ...... large breast cancer databases.
@en
Progesterone receptor status s ...... large breast cancer databases.
@nl
prefLabel
Progesterone receptor status s ...... large breast cancer databases.
@en
Progesterone receptor status s ...... large breast cancer databases.
@nl
P2093
P356
P1476
Progesterone receptor status s ...... large breast cancer databases.
@en
P2093
C Kent Osborne
Gary M Clark
Grazia Arpino
Richard M Elledge
Valerie-Jeanne Bardou
P304
P356
10.1200/JCO.2003.09.099
P407
P577
2003-05-01T00:00:00Z